Virginia Catalyst Grant Round 20 Is Open
Virginia Catalyst is accepting Letters of Intent for Grant Round 20, a competitive life-sciences commercialization funding round supporting projects that address major unmet needs for improving human health and strengthen Virginia’s life-sciences economy.
Letters of Intent are due September 25, 2026 at 5:00 PM Eastern. Only teams whose LOI meets Virginia Catalyst’s funding criteria will be invited to submit a full application, which is due October 16, 2026 at 5:00 PM Eastern.
Funding
Virginia Catalyst states that its competitive grant rounds generally make awards ranging from $200,000 to $800,000 per proposal for milestone-based project activities over approximately 12 to 18 months. The Round 20 page does not publish a separate round-specific total pool.
Who Can Apply
Eligible proposals must involve substantive collaboration between investigators from at least two Virginia research universities and an industry partner. Projects must address a large unmet human-health need, propose a product or service to be commercialized, demonstrate a commercialization pathway and Virginia economic impact, and satisfy the required match.
Mandatory Match
Virginia Catalyst requires a minimum 1:1 hard-dollar match. In-kind services and waived overhead do not count. Matching funds may come from qualifying unspent federal, state or foundation grants, equity capital, angel or venture funding, or other corporate sponsorship when the source permits the funds to be used as match. Matching-fund documentation must be approved before award funds can be released.
Priority Technology Areas
Virginia Catalyst identifies Virginia core strengths including bioinformatics, medical informatics, point-of-care diagnostics, and drug discovery and delivery. Projects are evaluated on market need, collaboration, scientific merit, commercialization, intellectual property, management, follow-on funding and Virginia economic impact.
Atlas Assessment
Atlas Opportunity Score: 90/100. The opportunity is strategically important because it offers substantial commercialization funding for collaborative human-health innovation, but the mandatory two-university collaboration and 1:1 hard-dollar match create significant qualification gates.
N9+ Fit Score: 68/100 conditional. A legitimate pathway may exist where the Nonagon N9+ remote physical examination platform is part of a new translational or commercialization project tied to point-of-care diagnostics, medical informatics, clinical validation or a differentiated product-development milestone. Atlas should not represent routine N9+ sales or ordinary deployment as sufficient. Any Dr. Miltie-led pursuit is on hold unless the required university collaborators and an acceptable hard-dollar match are independently verified and Marc approves any Dr. Miltie match commitment.
QC Healthcare Fit: 20/100 conditional. QC Healthcare may have a supporting clinical-validation or implementation role in a properly structured university-industry project, but it is not a standalone fit under the current funding criteria.
Next Action
Potential teams should identify two eligible Virginia research-university investigators, define a commercialization-ready human-health project, document the market need, technical milestones, intellectual-property and commercialization pathway, Virginia economic impact and source of the required hard-dollar match, then submit the LOI by September 25, 2026 at 5:00 PM Eastern.
Official sources: Virginia Catalyst Grant Round 20 application page, Virginia Catalyst FAQ, and Virginia Catalyst funding criteria.